VEGI Antibody (1A3): sc-53975

VEGI Antibody (1A3) is a mouse monoclonal IgG1 kappa light chain antibody that detects VEGI protein of human origin by western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), flow cytometry (FCM), and enzyme-linked immunosorbent assay (ELISA). VEGI Antibody (1A3) is available in both non-conjugated and various conjugated forms, including agarose, horseradish peroxidase (HRP), phycoerythrin (PE), fluorescein isothiocyanate (FITC), and multiple Alexa Fluor® conjugates. The vascular endothelial cell growth inhibitor (VEGI), also known as TNFRSF15 or TL1, is a crucial member of the tumor necrosis factor (TNF) superfamily, playing a significant role in regulating angiogenesis. VEGI is primarily located in endothelial cells and is expressed in various tissues, including the brain and reproductive systems, particularly during late developmental stages of embryogenesis. VEGI′s ability to inhibit endothelial cell proliferation is vital for controlling abnormal blood vessel formation, which is a hallmark of many diseases, including cancer. Furthermore, VEGI can function as an autocrine factor, inducing apoptosis in endothelial cells through the activation of multiple signaling pathways, including stress protein kinases and specific caspases. This multifaceted role underscores VEGI′s importance in maintaining vascular homeostasis and potential as a therapeutic target in diseases characterized by excessive angiogenesis.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

VEGI Antibody (1A3) References:

1. Inhibition of angiogenesis and breast cancer xenograft tumor growth by VEGI, a novel cytokine of the TNF superfamily.  |  Zhai, Y., et al. 1999. Int J Cancer. 82: 131-6. PMID: 10360832
2. Characterization of TNFRSF19, a novel member of the tumor necrosis factor receptor superfamily.  |  Hu, S., et al. 1999. Genomics. 62: 103-7. PMID: 10585776
3. VEGI, a new member of the TNF family activates nuclear factor-kappa B and c-Jun N-terminal kinase and modulates cell growth.  |  Haridas, V., et al. 1999. Oncogene. 18: 6496-504. PMID: 10597252
4. Vascular endothelial growth inhibitor (VEGI), an endogenous negative regulator of angiogenesis.  |  Metheny-Barlow, LJ. and Li, LY. 2006. Semin Ophthalmol. 21: 49-58. PMID: 16517446
5. Increased expression of extracellular proteins as a hallmark of human endothelial cell in vitro senescence.  |  Hampel, B., et al. 2006. Exp Gerontol. 41: 474-81. PMID: 16626901
6. Reduced vascular endothelial growth inhibitor (VEGI) expression is associated with poor prognosis in breast cancer patients.  |  Parr, C., et al. 2006. Angiogenesis. 9: 73-81. PMID: 16758268
7. Advancement in the research on vascular endothelial growth inhibitor (VEGI).  |  Duan, L., et al. 2012. Target Oncol. 7: 87-90. PMID: 22388993
8. VEGI Improves Outcomes in the Early Phase of Experimental Traumatic Brain Injury.  |  Zhou, Z., et al. 2020. Neuroscience. 438: 60-69. PMID: 32380270
9. VEGI downregulation is correlated with nodal metastasis and poor prognosis in lung adenocarcinoma.  |  Xu, Y., et al. 2021. Mol Clin Oncol. 14: 25. PMID: 33335733
10. Characterization of a novel TNF-like ligand and recently described TNF ligand and TNF receptor superfamily genes and their constitutive and inducible expression in hematopoietic and non-hematopoietic cells.  |  Tan, KB., et al. 1997. Gene. 204: 35-46. PMID: 9434163
11. VEGI, a novel cytokine of the tumor necrosis factor family, is an angiogenesis inhibitor that suppresses the growth of colon carcinomas in vivo.  |  Zhai, Y., et al. 1999. FASEB J. 13: 181-9. PMID: 9872942
12. TL1, a novel tumor necrosis factor-like cytokine, induces apoptosis in endothelial cells. Involvement of activation of stress protein kinases (stress-activated protein kinase and p38 mitogen-activated protein kinase) and caspase-3-like protease.  |  Yue, TL., et al. 1999. J Biol Chem. 274: 1479-86. PMID: 9880523

Monoclonal antibodies for mammalian and non-mammalian protein targets represent essentially all targets covered by polyclonal antibodies. Over 8,300 of our antibodies are offered as ImmunoCruz^® conjugates which eliminates the need for a secondary antibody.

Santa Cruz Biotechnology antibodies have over 360,000 research citations. Anti-VEGI Antibody (1A3) has 4 citations in a variety of scientific publications.

Primary antibodies like Anti-VEGI Antibody (1A3) for mammalian target proteins are recommended for the detection of a range of mammalian species, primarily of mouse, rat and human species. Many mammalian antibodies are also ideal for veterinary research and reactive with ovine, porcine, caprine, feline, canine, bovine and equine protein targets. Santa Cruz Biotechnology primary monoclonal antibodies are suitable for laboratory research applications and are not intended for diagnostic or therapeutic use.

VEGI Antibody (1A3) Specifications

Alternate Product Name: VEGI

Product Clone Name: 1A3

Classification: Primary Antibody

Clonality: Monoclonal Antibody

Antibody Isotype: IgG₁ kappa light chain

Amino Acids:

Epitope Target: VEGI

Epitope Species: human

Product Reactivity/Detection: VEGI

Species Reactivity/Detection: human

Additional Mammalian Reactivity: N/A

Additional Non-Mammalian Reactivity: N/A

Applications: WB, IP, IF, FCM, ELISA

Vialing Information: Each vial contains 200 µg IgG₁ kappa light chain in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin

Research Citations: 4 citations in various scientific publications

Available Conjugates/Forms for VEGI Antibody (1A3): AC: Agarose, AF488: Alexa Fluor^® 488, AF546: Alexa Fluor^® 546, AF594: Alexa Fluor^® 594, AF647: Alexa Fluor^® 647, AF680: Alexa Fluor^® 680, AF790: Alexa Fluor^® 790, FITC: Fluoroscein, HRP: Horseradish Peroxidase, PE: Phycoerythrin